Tenderwize
Zurück zur Suche

Open-House-Biologika-Rabattverträge 2025-17 - Agalsidase beta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 29, 2027 · 308 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-17 -Agalsidase beta

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

30 / 100

Risikofaktoren

The procedure is explicitly not a procurement under EU/German procurement law. Legal remedies are via social courts, wh...

No estimated value, no volume guarantees. Discount agreements may be unattractive if volumes are low.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of Agalsidase beta to the participating health insurance funds under discount agreements.
  • Open House procedure with no exclusivity and no negotiation.
Vollständige Zusammenfassung anzeigen

This is an Open House procedure for Rabattverträge (discount agreements) under §130a SGB V for the active ingredient Agalsidase beta. The lead buyer is Techniker Krankenkasse (TK) in cooperation with HEK and hkk. The contract is a non-exclusive framework without negotiation; no estimated value is provided. The deadline for submission is 2027-06-29, but contributions are possible at any time during the contract period (01.07.2025-30.06.2027). Only one lot is identified. The opportunity is open to all qualified pharmaceutical entrepreneurs who meet the eligibility criteria. The notice explicitly states this is not a public procurement subject to procurement law, and legal challenges go to social courts. No procurement documents were analyzed (only the XML notice).

Risiken

The procedure is explicitly not a procurement under EU/German procurement law. Legal remedies are via social courts, wh...

No estimated value, no volume guarantees. Discount agreements may be unattractive if volumes are low.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4(18) AMG with a valid marketing authorization for Agalsidase beta.
  • Registered seat in Germany, EU, or EEA (§9(2) AMG).

Eligibility

  • No criminal convictions or exclusion grounds (GWB §§123,124).

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria specified; contract is offered to all eligible participants without competitive award.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-17 - Agalsidase beta

Conclusion of pharmaceutical discount agreements for the active substance Agalsidase beta under the Open House procedure. No exclusivity, no negotiation, uniform conditions. Contract term 24 months (01.07.2025-30.06.2027).

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Jun 2025 - Jun 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria specified; contract is offered to all eligible participants without competitive award.

Frist

Deadline Jun 29, 2027

Vergabedetails

Veröffentlichungsdatum
25 May 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
336062-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3